Companies / Santa Cruz Biotechnology / Myo-inositol oxygenase (D-11)
Santa Cruz Biotechnology

Myo-inositol oxygenase (D-11) | Santa Cruz Biotechnology

mouse monoclonal IgG2a; Myo-inositol oxygenase (MIOX), also known as ALDRL6, is a renal-specific member of the Aldo-keto reductase family. It catalyzes the first committed step in the Myo-inositol metabolism pathway and is widely distributed in mammalian tissues. Human Myo-inositol oxygenase shares 91% and 96% sequence homology with mouse and pig Myo-inositol oxygenase homologs, respectively. Myo-inositol oxygenase is responsible for the oxidative cleavage of Myo-inositol (MI) and its epimer D-chiro inositol (DCI) to D-glucuronate. The dioxygen-dependent cleavage of the C1-C6 bond in Myo-inositol is accomplished through the utilization of the Fe(II)/Fe(III) binuclear iron center of MIOX. Myo-inositol oxygenase has also been implicated in complications of diabetes, including diabetic nephropathy.

Reviews


No reviews yet

ABOUT THE COMPANY

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research antibodies, siRNA and CRISPR Gene editing tools, biochemicals, labware and more recently has expanded into animal health care products. Santa Cruz Biotechnology has the highest commitment to quality and customer service.

  • See More